Targeted suppression of HO-2 gene expression impairs the innate anti-inflammatory and repair responses of the cornea to injury by Bellner, Lars et al.
Targeted suppression of HO-2 gene expression impairs the innate
anti-inflammatory and repair responses of the cornea to injury
Lars Bellner,1 Kiran A. Patil,1 Kirkland Castellano,1 Adna Halilovic,1 Michael W. Dunn,2
Michal Laniado Schwartzman1,2
(The first two authors contributed equally to the work)
1Department of Pharmacology, New York Medical College, Valhalla, NY; 2Department of Ophthalmology, New York Medical
College, Valhalla, NY
Purpose: Heme  oxygenase (HO)-2 is highly expressed in the corneal epithelium and is a component of the heme oxygenase
system that represents an intrinsic cytoprotective and anti-inflammatory system based on its ability to modulate leukocyte
migration and to inhibit expression of inflammatory cytokines and proteins via its products biliverdin/bilirubin and carbon
monoxide (CO). We have shown that in HO-2 null mice epithelial injury leads to unresolved corneal inflammation and
chronic inflammatory complications including ulceration, perforation and neovascularization. In this study, we explore
whether a localized corneal suppression of HO-2 is sufficient for disrupting the innate anti-inflammatory and repair
capability of the cornea.
Methods: Silencing hairpin RNA (shRNA) against HO-2 was administered subconjunctivally (100 ng/eye) as well as
topically (100 ng/eye) starting one day before corneal epithelial debridement and once daily, thereafter. The corneal
epithelium was removed using an Alger Brush in anesthetized mice. Re-epithelialization was assessed by fluorescein
staining using a dissecting microscope and image analysis. Inflammatory response was quantified by myeloperoxidase
activity. Levels of mRNA were measured by RT–PCR.
Results: Local injection of HO-2-specific shRNA led to a 50% reduction in corneal HO-2 mRNA. Administration of
HO-2-specific shRNA delayed corneal re-epithelialization when compared with the control shRNA-treated group by 14%,
20%, and 12% at days 3, 4, and 7 after injury, respectively (n=18–24). The observed delay in the wound repair process
in HO-2 shRNA treated mice was accompanied by a threefold and 3.5 fold increase in the neovascular response at days
4 and 7 after injury. Further, local knockdown of HO-2 lead to an aberrant chronic inflammatory response, as shown by
presence of high numbers of inflammatory cells still present in the cornea at day 7 after injury; 1.04±0.45×106 in HO-2
knockdown mice versus 0.14±0.03×106 inflammatory cells in control mice. Matrix metalloproteinase-2 (MMP-2) but not
MMP-9 increased following injury and remained elevated in the injured corneas of the HO-2 shRNA-treated eyes.
Conclusions: Corneal knockdown of HO-2 via local administration of HO-2-specific shRNA leads to delayed re-
epithelialization, increased neovascularization and an aberrant inflammatory response similar to what is observed in the
HO-2 null mouse. The elevated MMP-2 expression may contribute to the increase in neovascularization in corneas in
which HO-2 expression is suppressed.
The epithelium is the outermost layer of the cornea and
primarily functions as a protective barrier to avoid fluid loss
and  invasion  of  the  eye  by  pathogens  and,  through  its
interaction with the tear film, forms an absolutely smooth and
transparent refractive surface. The response of the corneal
epithelium  to  insults  is  rapid  and  consists  of  several
consecutive steps starting with immediate migration of the
remaining epithelial cells to cover the wound area followed
with proliferation and upward movement of cells to form a
multilayered  functional  structure,  all  processes  driven  by
growth factors and other factors released into the injured area
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by  epithelial  cells,  keratinocytes  and  to  some  extent  by
inflammatory cells invading the injured cornea [1,2].
The  heme  oxygenase  (HO)  system  has  emerged  as  a
fundamental endogenous cytoprotective (anti-oxidative) and
anti-inflammatory system in many tissues. HO catalyzes the
degradation of free heme to biliverdin and carbon monoxide
(CO), a reaction that is equally performed by the inducible as
well  as  the  constitutive  HO  isoforms,  HO-1  and  HO-2,
respectively  [3].  The  mechanisms  by  which  HO  affords
cytoprotection are thought to be attributed to the elimination
of excess cellular heme as well as the enzymatic products of
the HO system, i.e., CO and bilirubin. The characteristics of
HO-1 as an inducible enzyme support the view that it is the
primary component of the cytoprotective action exerted by the
HO  system.  Indeed,  upregulation  of  HO-1  suppresses  the
inflammatory response by either attenuating the expression of
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1144adhesion  molecules  and,  thus,  inhibiting  leukocyte
recruitment [4,5], by repressing the induction of cytokines and
chemokines  [6-10],  or  by  inhibiting  pro-inflammatory
hemoproteins  such  as  cyclooxygenase  (COX)-2  and
cytochrome P450 4B1 (CYP4B1) [11-14]. On the other hand,
HO-1 deficiency is associated with a chronically inflamed
state and increased leukocyte recruitment as reported in both
humans [15,16] and in mice [17,18] null for the HO-1 gene.
HO-2, by virtue of its constitutive and relatively constant
expression  in  most  tissues,  has  received  less  attention.
However,  its  distinct  properties  including  constitutive
expression,  activation  by  phosphorylation  [19,20]  and
additional binding site for heme [21] set it apart from HO-1.
Furthermore, the demonstration that HO-2 is cytoprotective
without  degrading  heme  [22,23]  implies  that  HO-2
participates not only in maintaining heme homeostasis but
also in cellular defense mechanisms against injury. To this
end,  studies  using  HO-2  null  mice  have  demonstrated  an
increased susceptibility to hyperoxic injury in the lung [24]
and to oxidative and ischemic injury in the brain [25,26].
In a series of studies, we have shown that the cornea of
human, rabbit and mouse exhibits HO activity and expresses
HO-1 in response to injury and oxidative stress in vitro and in
vivo [27-30] and that further induction of HO-1 alleviates
injury-induced ocular surface inflammation and accelerates
corneal  wound  healing  [27].  Recently,  we  showed  that
HO-2  displays  a  prominent  constitutive  expression  in  the
cornea that is localized primarily to the corneal epithelium
[29] and is the main contributor of HO activity in the healthy
cornea. The function of HO-2 in the avascular cornea is largely
unknown.  However,  recent  studies  using  HO-2  null  mice
implicates it as a key component of the corneal inflammatory
and repair response. In these studies, we showed that deletion
of the HO-2 gene markedly impairs the inflammatory and
reparative response of the cornea to epithelial injury [28,31]
and in a model of suture induced neovascularization [29].
Hence,  HO-2  deficiency  leads  to  unresolved  corneal
inflammation  and  chronic  inflammatory  complications
including  ulceration,  perforation  and  neovascularization.
Importantly, the outcomes of this deficiency was shown to be
reversed in part by supplementation of the HO metabolic
product, biliverdin [31].
Based on these studies and the finding of a substantial
expression of HO-2 in the normal corneal epithelium [28,
29],  it  is  reasonable  to  assume  a  functional  role  for  the
epithelial  HO-2  in  the  regulation  of  corneal  homeostasis.
However, the use of HO-2 null mice does not exclude the
possibility of systemic influence of HO-2 deletion on the
response of the cornea to injury. In this study, we used plasmid
DNA encoding HO-2 specific and non-specific shRNAs to
examine  whether  local  knockdown  of  the  HO-2  gene
interferes with corneal wound healing in vivo.
METHODS
Animal  experimentation:  All  animal  experiments  were
performed following an institutionally approved protocol in
accordance with the National Institutes of Health Guide for
the  Care  and  Use  of  Laboratory  Animals.  Mice  (C57bl6;
Jackson Laboratories, Bar Harbor, ME) were anesthetized
with  ketamine  (50  mg/kg)  and  xylazine  (20  mg/kg)
intramuscularly  and  a  drop  of  tetracaine-HCl  0.5%  was
applied to the eye to deliver local corneal anesthesia before
subjecting animals to injury. The corneal epithelium up to the
corneal/limbal border was removed using an Algerbrush II
with a 0.5-mm corneal rust ring remover (Alber Equipment
Co., Lago Vista, TX) as previously described [28]. Plasmids
carrying  HO-2  shRNA  (200  ng  /eye)  were  mixed  with
collagen (Atelocollagen, Koken Co. Ltd, Tokyo, Japan) and
then administered subconjunctivally adjacent to the limbal
border using a Hamilton syringe, (a total of 4 µl shRNA/
collagen-mix, 1 µl in each quadrant of the limbal border, was
injected) as well as topically (100 ng plasmid/eye in 4 µl)
starting one day before corneal epithelial debridement and
every  other  day  thereafter.  Wound  closure  and
neovascularization were measured at day 2, 4, and 7 after
injury. Digital images of the anterior surface were taken with
a Zeiss dissecting microscope using Axiovision 4.5 software
and  analyzed  by  Axiovision  4.5  software  (Carl  Zeiss,
Göttingen, Germany). Mice were euthanized at the indicated
time  points,  eyes  were  removed,  and  corneas,  free  of
conjunctival tissue, were dissected and processed for selected
analyses.
shRNA plasmids: The shRNAs were obtained from OriGene
Technologies, Inc. (Rockville, MD). The shRNA expression
cassette consists of a 29 bp target gene specific sequence, a 7
bp loop, and another 29 reverse complementary sequence, all
under  a  human  U6  promoter.  A  termination  sequence
(TTTTTT) is located immediately downstream of the second
29  bp  reverse  complementary  sequence  to  terminate  the
transcription  by  RNA  Pol  III.  The  29  bp  gene-specific
sequence was sequence-verified to ensure its match to the
target gene. The HO-2 oligonucleotide sequence was 5′-TGA
GTC  AGA  GAA  GAA  CTC  TAT  GGC  ACC  AG’3′.  A
plasmid containing shRNA directed against green fluorescent
protein (GFP) was used as a negative control. The shRNA
plasmids were transformed and amplified in E. coli according
to  the  manufacturer’s  instructions.  Plasmid  DNA  was
extracted using the Plasmid Midi Prep (Qiagen, Valencia,
CA).
Histology: Dissected corneas were washed twice with PBS
and  fixed  in  4%  paraformaldehyde-PBS  for  1  h  at  4  °C.
Corneas were washed five times with PBS, placed in 30%
sucrose for 24 h and embedded in optimal cutting temperature
(OCT) compound (Sakura Finetek, Torrence, CA). Cryostat
sections were cut transversely into 5–7 µm thick sections,
stained with Hematoxylin-Eosin and mounted on microscopic
Molecular Vision 2011; 17:1144-1152 <http://www.molvis.org/molvis/v17/a129> © 2011 Molecular Vision
1145slides  in  Cytoseal  XYL  (Richard-Allan  Scientific,
Kalamazoo, MI).
Myeloperoxidase  (MPO)  activity:  Measurement  of  MPO
activity  was  used  to  quantify  polymorphonuclear  cells
(PMNs) in dissected corneas as previously described [28]. In
brief,  tissues  were  homogenized  in  potassium  phosphate
buffer  (pH  6.0)  containing  0.5%
hexadecyltrimethylammonium  bromide,  followed  by  three
cycles of sonication and freeze–thaw. The particulate matter
was  removed  by  centrifugation,  and  MPO  activity  in  the
supernatant  was  measured  by  spectrophotometry  using  o-
dianisidine  dihydrochloride  reduction  as  a  colorimetric
indicator. Calibration curves for conversion of MPO activities
to  PMN  number  were  established  with  PMNs  that  were
collected from zymosan A-induced peritonitis in mice.
Real-time polymerase chain reaction (PCR): Corneas were
aseptically dissected from eyes and cleaned in sterile PBS
(4  °C)  under  a  dissecting  microscope  to  remove  all  non-
corneal tissue. Total RNA was isolated using the RNeasy®
Plus Micro Kit (Qiagen, Germantown, MD) and RNA was
quantitated using a Nanodrop spectrophotometer (Nanodrop
Technologies,  Wilmington,  DE).  Reverse  transcription
reaction of total RNA was performed using the qScript™
cDNA Synthesis Kit (Quanta BioSciences, Inc., Gaithersburg,
MD)  according  to  the  manufacturer’s  instruction.
Quantitative real-time PCR was performed using PerfeCTa™
SYBR® Green FastMix™ Kit (Quanta BioSciences, Inc.) and
the Mx3000 real-time PCR system (Stratagene, La Jolla, CA).
Specific primers, purchased from Gene Link™ (Hawthorne,
NY), were designed using Primerbank based on published
sequences (GenBank) and were as follows: 18S sense, 5′-TGT
CTC AAA GAT TAA GCC ATG CAT-3′ and anti-sense, 5′-
AAC CAT AAC TGA TTT AAT GAG CCA TTC-3′; HO-1
sense, 5′-TCC AGA CAC CGC TCC TCC AG-3′ and anti-
sense, 5′-GGA TTT GGG GCT GCT GGT TTC-3′; HO-2
sense, 5′-TAC TTC ACA TAC TCA GCC CT-3′ and anti-
sense, 5′-ATG GGC CAC CAG CAG CTC TG-3′; MMP-2
sense,  5′-GAC  CTT  GAC  CAG  AAC  AAC  ATC-3′  and
antisense,  5′-CAT  CCA  CGG  TTT  CAG  GGT  CC-3′;
MMP-9 sense, 5′-TGC CCA TTT CGA CGA CGA C-3′ and
antisense,  5′-GTG  CAG  GCC  GAA  TAG  GAG  C-3′.
Quantitative analysis was performed as previously described
[27.29].
Statistical analysis: Student’s t-test was used to evaluate the
significance  of  differences  between  groups  and  multiple
comparisons were performed by regression analysis and one-
way  ANOVA.  P  values  less  than  0.05  were  considered
significant. All data are presented as mean±SEM.
RESULTS
Local  administration  of  HO-2  shRNA  suppresses  corneal
HO-2 but not HO-1 mRNA expression: HO-2 is constitutively
expressed in the cornea at relatively high levels and its level
after injury remains largely unchanged [30]. As seen in Figure
1A,  local  injection  of  HO-2  shRNA  into  the  conjunctiva
adjacent to the limbal border caused a 50% decrease in the
level of HO-2 mRNA as compared to injection with control
shRNA. The level of HO-1 following HO-2 shRNA treatment
was largely unaltered (Figure 1B).
Local suppression of HO-2 delays corneal wound healing:
Epithelial  injury  produced  a  consistent  wound
(7.03±0.032 mm2, n=47) that exhibited a linear rate of re-
epithelialization  in  non-specific  (control)  shRNA-treated
mice with 12.87%±1.31%, 49.87%±1.86%, 81.09%±2.25%,
88.65%±2.20%, and 94.98%±1.45% wound closure at days 1,
2, 3, 4, and 7 after injury, respectively (Figure 2A). the rate of
re-epithelialization  was  not  significantly  different  from
untreated  mice.  In  contrast,  re-epithelialization  of  corneal
wounds (6.04±0.16 mm2, n=4) in HO-2 shRNA-treated mice
was blunted by 0.25%, 7%, 14% 20%, and 12% at days 1, 2,
3, 4, and 7 after injury as compared with mice treated with
control shRNA (Figure 2B).
Local suppression of HO-2 increases injury-induced corneal
neovascularization: We have previously shown that in the
HO-2  null  mice  epithelial  injury  causes  massive  corneal
neovascularization  [28].  We  examined  whether  localized
suppression of corneal HO-2 expression also increases the
degree of neovascularization. As seen in Figure 3A, eyes
Figure  1.  Effect  of  local  HO-2
knockdown on HO-2 and HO-1 mRNA
levels. Corneal A: HO-2, and B: HO-1
mRNA levels after control- and HO-2-
shRNA-treatment.  (**p<0.01  from
control-shRNA-treated mice, n=2–4).
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1146treated with HO-2-specific shRNA showed increased corneal
neovascularization; the total vessel length was 6.20±0.83 and
14.63±3.14 mm at days 4 and 7, respectively, compared to
1.97±0.25  and  4.02±0.39  mm  at  days  4  and  7  in  control
shRNA-treated mice (n=10–21; Figure 3B).
HO-2 suppression alters the inflammatory response in the
injured  cornea:  In  WT  mice,  the  corneal  inflammatory
response in response to epithelial injury is characterized by a
transient influx of inflammatory cells into the stroma, whereas
in the HO-2 null mice the inflammatory response remains
unresolved [28]. In this study, local HO-2 silencing showed a
similar result (Figure 4), causing the number of inflammatory
cells to remain elevated at the end of the experimental period
of 7 days; the number of neutrophils per cornea, as measured
by  MPO-activity,  being  (in  millions/cornea)  0.23±0.05,
0.54±0.15, 0.61±0.17, and 1.04±0.45 at days 2, 3, 4, and 7
after  injury,  correspondingly  as  compared  to  0.26±0.09,
0.51±0.20, 0.69±0.22, and 0.14±0.03 at days 2, 3, 4, and 7 in
control shRNA treated mice (n=6–11).
Induction of HO-1 is a rapid and transient cytoprotective
response to injury in many tissues including the cornea [28,
29,32,33]. We have shown that in the absence of HO-2 this
response is compromised in the injured cornea [28,29]. This
effect was also seen with local knockdown of HO-2. As seen
Figure  2.  Effect  of  local  HO-2
knockdown on corneal wound healing.
A:  Fluorescein-stained  corneas  after
injury  in  control-  and  HO-2-shRNA-
treated  mice.  B:  Wound  closure  as
percent from day 0 (*p<0.05 from non-
treated,  and  control  shRNA  treated
mice, n=3–24).
Figure  3.  Effect  of  local  HO-2
knockdown  on  the  injury  induced
corneal  neovascularization.  A:
Photographs  showing
neovascularization  in  control-  and
HO-2 shRNA-treated mice at days 4,
and 7 after epithelial debridement. B:
Neovascularization  expressed  as  total
length  of  penetrating  vessels
(***p<0.001  from  control-shRNA-
treated mice, n=10–21).
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1147in Figure 5A, in the control shRNA-treated eyes, corneal
HO-1 mRNA levels increased by 10-fold within 24 h after
injury, remained elevated by 5–6 fold through day 4 and
decreased  to  levels  of  2.5  fold  higher  than  in  uninjured
corneas. In contrast, in the HO-2 shRNA-treated eyes, HO-1
induction in response to injury was markedly blunted. HO-1
mRNA rose to levels of 2.5 fold higher than uninjured corneas
and remained roughly unchanged at levels not significant
from those in the uninjured cornea (Figure 5B). The levels of
HO-2 mRNA in the control shRNA- and the HO-2 shRNA-
treated corneas remained largely unchanged throughout the
duration of the experiment (Figure 5C,D). The HO-2 mRNA
levels  in  the  HO-2  shRNA-treated  corneas  were  however
significantly  reduced  as  compared  to  uninjured  control
shRNA-treated corneas at days 1, 2, and 3, but not at days 4
and 7, possibly due to HO-2 mRNA brought into the tissue by
infiltrating inflammatory cells (Figure 5D).
Matrix metalloproteinases (MMPs) have been shown to
play  an  important  role  in  epithelial  repair  and  stromal
remodeling following injury [34,35]. In a recently published
study, we showed that both MMP-2 and MMP-9 mRNA are
expressed in corneas of HO-2 null mice, and that the mRNA
levels of MMP-2, which peaked at day 7 after injury, were
significantly lowered in corneas of biliverdin-treated mice,
that  in  addition  developed  less  severe  corneal  epithelial
defects  and  reduced  corneal  neovascularization  [31].
Therefore,  in  this  study,  we  examined  whether  local
knockdown of HO-2 affect the expression of these MMPs in
response to injury and during wound healing. As seen in
Figure 6A,B, corneal MMP-2 and MMP-9 mRNA levels were
Figure 4. Effect of local HO-2 knockdown on the injury induced
inflammatory  response.  Corneal  MPO  activity  in  control-  and
HO-2-shRNA-treated mice at days 2, 3, 4, and 7 after epithelial
debridement (*p<0.05 from control-shRNA-treated mice, n=6–12).
elevated in response to injury with significantly higher levels
of MMP-2 at days 1, 4, and 7 after injury and MMP-9 at days
1, 3, 4, and 7 after injury, as compared to uninjured corneas.
Interestingly,  the  levels  of  MMP-2  and  MMP-9  mRNA
seemed higher at day 7 in the corneas of mice treated with
HO-2 shRNA as compared to control shRNA-treated mice
(Figure 6A,B).
DISCUSSION
Inflammation is a vital physiologic response to injury in living
tissues and, when tightly controlled, contributes to normal
healing and repair; it enables and crucially drives tissue repair
by stimulation of resident cells to migrate and proliferate into
the wound site, but severely disturbs wound healing processes
when it is prolonged or overly exaggerated. Hence, an ordered
execution and resolution of inflammation is an essential step
toward  wound  healing;  it  requires  balanced  and  defined
formation of pro- as well as anti-inflammatory signals which
orchestrate  a  complex  and  well  controlled  biologic  and
biochemical process involving tissue cells and cells of the
immune system. We have previously identified the HO-2 as
a  key  anti-inflammatory  and  cytoprotective  signal  in  the
cornea  and  showed  that  its  deletion  impairs  the  corneal
inflammatory and repair response; HO-2-deficient corneas
respond to injury with exaggerated inflammation and lack of
resolution leading to impaired wound healing, perforation,
ulceration and neovascularization [28].
The  present  study  was  undertaken  to  evaluate  the
consequences  of  local  rather  than  global  suppression  of
HO-2 to the inflammatory and repair response of the cornea
to  injury.  The  intracellular  delivery  of  small  interfering/
inhibitory RNA is a therapeutic strategy to transiently block
gene expression with great specificity and potency and an
excellent alternative to other genetic knockdown methods for
the  analysis  of  loss-of-function  phenotypes;  it  can  be
employed locally and at any stage of the experiment. Two
silencing  RNA  strategies  utilize  either  synthetic  double
stranded RNA or plasmid DNA encoding a shRNA [36,37];
both have been shown to be of great value in knocking down
genes in a variety of biologic systems. Both strategies have
been  used  successfully  to  locally  suppress  the  corneal
expression of several genes including vascular endothelial
growth factor (VEGF) and cytochrome P450 4B1 (CYP4B1)
in vivo under various experimental conditions [38-43]. We
have recently used this strategy to knockdown HO-2 in human
corneal epithelial cells and showed that deficiency in HO-2
impairs wound closure in vitro [30]. In this study, we used
plasmid  DNA  encoding  HO-2  specific  and  non-specific
shRNAs to examine whether local knockdown of HO-2 gene
interferes with corneal wound healing in vivo and corneal
epithelial cell proliferation and migration in vitro. Our results
clearly indicate that this approach is working; subconjunctival
injection of HO-2-specific but not the non-specific control
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cornea.
Similar to data obtained with the HO-2 null mice [28], in
situ suppression of HO-2 in WT mice was associated with
attenuation of corneal wound healing. Thus, wound closure
was completed by day 7 after injury in corneas treated with
nonspecific  shRNA,  whereas,  wound  healing  was
significantly  impaired  in  HO-2  specific  shRNA-treated
corneas showing a closure of the wound of only about 70% at
day 7 after injury. The impaired healing was also associated
with  increased  corneal  neovascularization,  a  finding
consistent with previous studies linking deficiency in HO-2
expression to increased angiogenesis [28,29,31]. In all, the
morphological  consequences,  i.e.,  impaired  healing  and
Figure  5.  Effect  of  local  HO-2
knockdown  on  injury  induced  HO-1
mRNA expression and on HO-2 mRNA
expression. Corneal HO-1 mRNA levels
in  A:  control  shRNA  and  B:  HO-2-
shRNA-treated corneas 1, 2, 3, 4, and 7
days  post  epithelial  debridement
(*p<0.05;  **p<0.01  from
corresponding uninjured corneas, n=5–
7). Corneal HO-2 mRNA levels in C:
control shRNA and D: HO-2-shRHA-
treated  corneas  in  uninjured  corneas,
and 1, 2, 3, 4, and 7 days post epithelial
debridement  (*p<0.05;  **p<0.01;
***p<0.001  from  control  shRNA-
treated uninjured corneas, n=5–10).
Figure  6.  Effect  of  local  HO-2
knockdown on injury induced MMP-2
and MMP-9 mRNA expression. Corneal
mRNA  levels  of  A:  MMP-2  and  B:
MMP-9  in  uninjured  corneas  and  in
control-  and  HO-2-shRNA-treated
corneas 2, 4, and 7 days post epithelial
debridement (*p<0.05 from uninjured,
n=2–5).
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were similar whether HO-2 expression was inhibited locally
or depleted globally.
It is recognized that leukocytes are not only capable of
amplifying  the  inflammatory  response,  but  are  also
significantly involved in the repair process [44]. Gan et al.
[45]  showed  in  two  rabbit  models  of  corneal  injury
(Photorefractive keratectomy [PRK] and a standardized alkali
corneal wound) that corneal epithelial healing rate is delayed
in the absence of PMNs in vivo and PCNA expression, a
marker  for  cell  proliferation,  increases  in  the  presence  of
leukocytes.  Other  studies  showed  that  limiting  neutrophil
infiltration to the cornea attenuated the inflammatory response
and accelerated wound closure [46,47], whereas, exaggerated
influx is linked to impaired resolution and repair and chronic
inflammation as was demonstrated in the HO-2 null mice
[28,29,31]. In accordance with our previous studies, wound
healing was associated with neutrophil infiltration that peaked
in numbers at day 4 after injury in control shRNA-treated
mice, but stayed elevated in the HO-2 shRNA-treated mice,
thus supporting the notion that HO-2 deletion interferes with
resolution.
We  have  previously  shown  that  HO-2  expression  is
heavily localized to the corneal epithelium, which is likely the
largest source of HO activity in the uninjured cornea. During
injury,  however,  inflammatory  cells  invading  the  cornea
import HO activity; the majority of this activity appears to be
driven by the inducible HO-1 [48,49]. We have also shown
that induction of HO-1, which constitutes a central defense
response to injury, is impaired in the absence of HO-2 [28].
The blunted HO-1 induction in the cornea in response to injury
in mice null for HO-2 was also observed in corneas in which
HO-2 was locally suppressed. The nature of the regulatory
interactions  between  these  two  isoforms,  whose  catalytic
activity and potency are identical, is unknown. However, in
view of reports showing that HO-1 expression and activity are
maximal during the resolution phase and that induction of
HO-1 expression promotes resolution whereas inhibition of
HO  activity  is  pro-inflammatory  [4,27-29,33,50-52],  it  is
reasonable  to  assume  that  this  blunted  response  may
contribute  to  the  diminished  defense  against  injury  and
consequently to the exaggerated inflammatory response in the
HO-2 shRNA-treated eyes.
Epithelial  injury  was  also  associated  with  a  distinct
increase in MMP-2 and MMP-9 expression. The expression
of both MMP-2 and MMP-9 has been shown to increase in
response to injury and contribute to epithelial wound repair
[34,35]. On the other hand, studies with MMP-2 null mice
demonstrated  decreased  corneal  neovascularization  in
response to removal of the corneal epithelium [53]. In this,
and in our previous study, MMP-2 mRNA expression appears
to be intimately related to corneal neovascularization. Bellner
et  al.  [31]  showed  that  lingering  and  elevated  levels  of
MMP-2 mRNA in response to epithelial debridement were
significantly lowered in corneas from HO-2 null mice treated
with biliverdin. In this study an increased angiogenic response
was  observed  in  the  HO-2  shRNA-treated  corneas  that
showed a tendency of elevated levels of MMP-2 mRNA at day
7 after injury as compared to control shRNA-treated corneas.
To  this  end,  we  performed  a  full-scale  gene  microarray
comparing  WT  and  HO-2  null  corneas;  preliminary  data
demonstrated again a close relationship between HO-2 and
MMP-2 expression where deletion of the HO-2 gene was
associated  with  a  sixfold  increase  in  MMP-2  expression
(Bellner, unpublished data). The nature of this relationship
with regard to corneal response to injury needs to be further
explored.
It  has  become  clear  that  a  functioning  HO  system  is
crucial for the anti-inflammatory circuits in the cornea, and
that enhancement through treatment with stannous chloride of
wild type mice [27], or partial replenishment in the shape of
one of its metabolic products, biliverdin [29,31]. It is possible
that  corneal  epithelial  HO-2  plays  a  significant  role  in
regulating this critical wave of neutrophils to the cornea. The
local knockdown of HO-2 impairs this ability while global
knockout not only negates it but also alters the characteristics
of the infiltrated cells [28]. Additional studies are needed to
explore the role of corneal HO-2 in regulating neutrophil
infiltration and resolution.
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